首页 > 最新文献

Current pulmonology reports最新文献

英文 中文
Correction: Interstitial Pneumonia with Autoimmune Features: Implications for Clinical Practice 更正:具有自身免疫特征的间质性肺炎:对临床实践的启示
IF 0.6 Pub Date : 2023-04-05 DOI: 10.1007/s13665-023-00305-0
Derrick Cleland, Matheni Sathananthan, N. Jeganathan
{"title":"Correction: Interstitial Pneumonia with Autoimmune Features: Implications for Clinical Practice","authors":"Derrick Cleland, Matheni Sathananthan, N. Jeganathan","doi":"10.1007/s13665-023-00305-0","DOIUrl":"https://doi.org/10.1007/s13665-023-00305-0","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49590422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Quality of Sleep in Healthy Adults 提高健康成年人的睡眠质量
IF 0.6 Pub Date : 2023-04-01 DOI: 10.1007/s13665-023-00304-1
R. Scott, Alcibíades J. Rodríguez
{"title":"Improving Quality of Sleep in Healthy Adults","authors":"R. Scott, Alcibíades J. Rodríguez","doi":"10.1007/s13665-023-00304-1","DOIUrl":"https://doi.org/10.1007/s13665-023-00304-1","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44749123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Interventional Pulmonologist Education and Training 介入性肺病学家的教育与培训
IF 0.6 Pub Date : 2023-03-21 DOI: 10.1007/s13665-023-00303-2
B. C. Adkinson, Hans J Lee
{"title":"Interventional Pulmonologist Education and Training","authors":"B. C. Adkinson, Hans J Lee","doi":"10.1007/s13665-023-00303-2","DOIUrl":"https://doi.org/10.1007/s13665-023-00303-2","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46124084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstructive Sleep Apnea in African Americans: A Literature Review 非裔美国人的阻塞性睡眠呼吸暂停:文献综述
IF 0.6 Pub Date : 2023-01-30 DOI: 10.1007/s13665-023-00300-5
Bianca Stewart, P. Barletta, B. Sorondo, A. Abreu, A. Chediak
{"title":"Obstructive Sleep Apnea in African Americans: A Literature Review","authors":"Bianca Stewart, P. Barletta, B. Sorondo, A. Abreu, A. Chediak","doi":"10.1007/s13665-023-00300-5","DOIUrl":"https://doi.org/10.1007/s13665-023-00300-5","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42760664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Cancer and Lung Transplantation 肺癌和肺移植
IF 0.6 Pub Date : 2023-01-28 DOI: 10.1007/s13665-023-00301-4
R. Jablonski
{"title":"Lung Cancer and Lung Transplantation","authors":"R. Jablonski","doi":"10.1007/s13665-023-00301-4","DOIUrl":"https://doi.org/10.1007/s13665-023-00301-4","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45469429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Affecting Rate of Pleural Fluid Accumulation in Patients with Malignant Pleural Effusions 影响恶性胸腔积液患者胸腔积液率的因素
IF 0.6 Pub Date : 2023-01-23 DOI: 10.1007/s13665-023-00299-9
D. Sethi, V. Kouritas, E. Mishra
{"title":"Factors Affecting Rate of Pleural Fluid Accumulation in Patients with Malignant Pleural Effusions","authors":"D. Sethi, V. Kouritas, E. Mishra","doi":"10.1007/s13665-023-00299-9","DOIUrl":"https://doi.org/10.1007/s13665-023-00299-9","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47851884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and Emerging Therapies for COVID-19 in Lung Transplantation. 肺移植中当前和新兴的COVID-19治疗方法。
Pub Date : 2023-01-01 DOI: 10.1007/s13665-023-00302-3
Daniel Z P Friedman, Natasha N Pettit, Erica MacKenzie, Jennifer Pisano

Purpose of review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.

Recent findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).

Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.

回顾目的:在过去三年中,2019冠状病毒病(COVID-19)大流行的形势发生了迅速变化。与此同时,科学界和医学界报告了许多与感染的流行病学、传播、诊断和治疗有关的新发现。我们回顾了COVID-19治疗方法的相关研究,重点是它们在肺移植受体中的应用。最近的发现:已被充分研究用于治疗COVID-19的药物包括抗病毒药物(remdesivir、nirmatrelvir/ritonavir、molnupiravir)、单克隆抗体和免疫调节剂(例如,皮质类固醇和托珠单抗)。总结:瑞德西韦仍然是治疗轻中度COVID-19的基本疗法。尽管在门诊治疗中对轻中度COVID-19非常有效,但利托那韦增强的nirmatrelvir在肺移植受者中的应用有限,因为药物-药物相互作用明显。单克隆抗体虽然有用,但受新病毒变体出现的影响最大。
{"title":"Current and Emerging Therapies for COVID-19 in Lung Transplantation.","authors":"Daniel Z P Friedman,&nbsp;Natasha N Pettit,&nbsp;Erica MacKenzie,&nbsp;Jennifer Pisano","doi":"10.1007/s13665-023-00302-3","DOIUrl":"https://doi.org/10.1007/s13665-023-00302-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.</p><p><strong>Recent findings: </strong>Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).</p><p><strong>Summary: </strong>Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.</p>","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9493812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Post COVID Interstitial Lung Abnormalities-Incidence and Management. 新冠肺炎后间质性肺异常的发病率和管理。
Pub Date : 2023-01-01 Epub Date: 2023-04-11 DOI: 10.1007/s13665-023-00307-y
Mark Robertshaw, Corey D Kershaw

Purpose of review: This review aims to summarize the available literature to identify the incidence and risk factors for persistent interstitial lung abnormalities (ILAs) following hospitalization for COVID-19. The current and prospective treatment options are reviewed in an effort to help pulmonary practitioners care for this burgeoning patient population.

Recent findings: Statistical modeling suggests that 11.7% of all patients hospitalized with COVID-19 have irreversible fibrotic features on long-term follow-up imaging.

Summary: The available evidence suggests that up to 30% of patients have ILAs following COVID-19 hospitalization. The radiographic abnormalities improve or resolve in a majority of these patients. However, estimates suggest that up to one-third of these patients have irreversible fibrotic features. Clinical trials of the impact of anti-fibrotic agents are ongoing. As there continue to be thousands of COVID-19 hospitalizations in the USA each week, the management of post-COVID ILAs will become a common problem for the pulmonary practitioner.

综述目的:本综述旨在总结现有文献,以确定新冠肺炎住院后持续性间质性肺异常(ILAs)的发病率和危险因素。对目前和未来的治疗方案进行了审查,以帮助肺科医生照顾这一迅速增长的患者群体。最近的发现:统计模型表明,在所有新冠肺炎住院患者中,11.7%的患者在长期随访成像中具有不可逆的纤维化特征。摘要:现有证据表明,高达30%的患者在新冠肺炎住院后患有ILA。大多数患者的放射学异常得到改善或解决。然而,据估计,这些患者中有多达三分之一具有不可逆的纤维化特征。抗纤维化药物影响的临床试验正在进行中。由于美国每周仍有数千人因新冠肺炎住院,新冠肺炎后ILA的管理将成为肺科医生的常见问题。
{"title":"Post COVID Interstitial Lung Abnormalities-Incidence and Management.","authors":"Mark Robertshaw,&nbsp;Corey D Kershaw","doi":"10.1007/s13665-023-00307-y","DOIUrl":"10.1007/s13665-023-00307-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to summarize the available literature to identify the incidence and risk factors for persistent interstitial lung abnormalities (ILAs) following hospitalization for COVID-19. The current and prospective treatment options are reviewed in an effort to help pulmonary practitioners care for this burgeoning patient population.</p><p><strong>Recent findings: </strong>Statistical modeling suggests that 11.7% of all patients hospitalized with COVID-19 have irreversible fibrotic features on long-term follow-up imaging.</p><p><strong>Summary: </strong>The available evidence suggests that up to 30% of patients have ILAs following COVID-19 hospitalization. The radiographic abnormalities improve or resolve in a majority of these patients. However, estimates suggest that up to one-third of these patients have irreversible fibrotic features. Clinical trials of the impact of anti-fibrotic agents are ongoing. As there continue to be thousands of COVID-19 hospitalizations in the USA each week, the management of post-COVID ILAs will become a common problem for the pulmonary practitioner.</p>","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9551072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Management of Sarcoidosis: When to Treat, How to Treat and for How Long? 结节病的治疗:何时治疗,如何治疗,治疗多久?
IF 0.6 Pub Date : 2022-11-29 DOI: 10.1007/s13665-022-00298-2
E. Fraser, P. Weeratunga, L. Ho
{"title":"Management of Sarcoidosis: When to Treat, How to Treat and for How Long?","authors":"E. Fraser, P. Weeratunga, L. Ho","doi":"10.1007/s13665-022-00298-2","DOIUrl":"https://doi.org/10.1007/s13665-022-00298-2","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46514934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbid Narcolepsy and Obstructive Sleep Apnea: A Review 发作性睡病与阻塞性睡眠呼吸暂停共病:综述
IF 0.6 Pub Date : 2022-11-15 DOI: 10.1007/s13665-022-00297-3
K. Wojnowski, M. Mayo, Jose Carlos Garcia Blanco, A. Abreu, A. Chediak
{"title":"Comorbid Narcolepsy and Obstructive Sleep Apnea: A Review","authors":"K. Wojnowski, M. Mayo, Jose Carlos Garcia Blanco, A. Abreu, A. Chediak","doi":"10.1007/s13665-022-00297-3","DOIUrl":"https://doi.org/10.1007/s13665-022-00297-3","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42420917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current pulmonology reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1